Systematic review of the complement components as potential biomarkers of pre-eclampsia: pitfalls and opportunities

TL;DR

This systematic review explores how components of the complement system might serve as biomarkers for pre-eclampsia, highlighting both promising findings and challenges in current research.

Contribution

The study systematically reviews complement component measurements in pre-eclampsia, identifying patterns and methodological issues.

Findings

Reduced levels of C4, C3, and factor H were observed in pre-eclampsia.

Increased levels of C4d, Bb, factor D, C3a, C5a, and C5b-9 indicate excessive complement activation.

Lack of experimental uniformity and biased cohort selection hinder reliable conclusions.

Abstract

The complement system (C) is a crucial component of the innate immune system. An increasing body of research has progressively shed light on the pivotal role of C in immunological tolerance at the feto-maternal interface. Excessive C activation or impaired C regulation may determine the onset of pregnancy-related pathological conditions, including pre-eclampsia (PE). Thus, several studies have investigated the presence of C components or split products in blood matrixes (i.e., plasma, serum), urine, and amniotic fluid in PE. In the current study, we systematically reviewed the currently available scientific literature reporting measurements of C components as circulating biomarkers in PE, based on a literature search using Pubmed, Scopus, and Embase databases. A total of 41 out of 456 studies were selected after full-text analysis. Fourteen studies (34.1%) were identified as measuring the blood concentrations of the classical pathway, 5 (12.1%) for the lectin pathway, 28 (68.3%) for the alternative pathway, 17 (41.5%) for the terminal pathway components, and 16 (39%) for C regulators. Retrieved results consistently reported C4, C3, and factor H reduction, and increased circulating levels of C4d, Bb, factor D, C3a, C5a, and C5b-9 in PE compared to normal pregnancies, depicting an overall scenario of excessive C activation and aberrant C regulation. With evidence of C activation and dysregulation, C-targeted therapy is an intriguing perspective in PE management. Moreover, we also discussed emerging pitfalls in C analysis, mainly due to a lack of experimental uniformity and biased cohort selection among different studies and laboratories, aiming to raise a more comprehensive awareness for future standardization.

https://www.crd.york.ac.uk/prospero/, identifier CRD42024503070.

Figures